Novadaq Updates on OPTTX Data Reported at Euroretina

Friday, May 30, 2008 General News
Email Print This Page Comment bookmark
Font : A-A+

TORONTO, May 29 /PRNewswire-FirstCall/ - Novadaq(R) Technologies Inc.(TSX: NDQ), a developer of real-time medical imaging and image guidancesystems for the operating room, today announced that ophthalmologists fromSacco Hospital in Milan, Italy reported independent 12-month follow-up data onpatients treated with the OPTTX(R) System in commercial practice at the recentEuroretina Conference held in Vienna Austria. The 12 month visual acuity (VA)data for those wet-AMD patients followed, some of whom had failed othertreatments, continued to support the previously reported six-month datapresented at the Association for Research in Vision and OphthalmologyConference in April 2008 in Fort Lauderdale, FL.

At 12 months, 23 patients were evaluable and the VA for a substantialmajority (19, or 83%) of patients studied remained stable or improved.Fourteen of the 23 (61%) had no change or showed a 1-6 line improvement in VA.Five patients lost up to 3 lines and 4 patients lost more than 3 lines in VA.The treating ophthalmologists concluded that the OPTTX technique was safe andreproducible. This study suggests that treatment with OPTTX can be used as analternative to the anti-VEGF drugs and that it appears that it can be safelyapplied before, after or in combination with anti-VEGF injections.

"We have been using the OPTTX System in our practice for the past eighteenmonths. OPTTX has allowed us to stabilize or improve vision in patients, manywho had failed previous therapies, and really had no other treatmentalternatives," said Giovanni Staurenghi, Professor of Ophthalmology, ChairmanEye Clinic, Director II School of Ophthalmology, Department of ClinicalScience Luigi Sacco, Sacco Hospital, University of Milan. "Most importantly,the twelve-month follow-up data demonstrates that the treatment with OPTTX issustainable."

"I have spent the last five years working with OPTTX and its predecessorsfor the treatment of wet AMD and have consulted with other ophthalmologiststhroughout Europe who were learning to use it," noted Dr. Chiara Veronese,Consultant Ophthalmologist. "The past year has been particularly rewarding inthat we have followed patients treated with OPTTX in both Milan and inCoventry and have seen benefits from its use."

The OPTTX-2N1 System, using the same core technology as the commerciallyavailable SPY(R) System, is a single device that performs multiple functions.The OPTTX System is designed to enable ophthalmologists and those trained inretinal subspecialties to diagnose, treat and provide on-going management ofpatients suffering from wet AMD. As the only imaging device with the abilityto visualize the disease state of wet AMD during treatment, OPTTX allows theophthalmologist to accurately diagnose and treat by targeting and closing theabnormal feeder vessels in real-time, within a single patient visit. OPTTXalso allows for immediate confirmation of the effectiveness of the treatment.

About Novadaq Technologies

Novadaq Technologies Inc. commercializes real-time imaging and imageguidance systems for use in the operating room. With one set of proprietarycore technologies, Novadaq's products have multiple applications. Novadaq'sSPY System enables cardiac surgeons to diagnose intra-operatively by visuallyassessing coronary vasculature and bypass graft functionality during thecourse of heart bypass surgery. The SPY System is also indicated for useduring other surgeries, such as cardiovascular, plastic, reconstructive, organtransplant and urological procedures. SPY can be used to visualize bloodvessels, tumors, tumor margins and the lymphatic system. Novadaq introducedPINPOINT(TM), its first minimally invasive imaging system for autofluorescencein October 2007. PINPOINT allows surgeons to differentiate between healthy andcancerous tissue in the lung and other hollow organs. Further expanding itsportfolio of minimally invasive products

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store